GlaxoSmithKline
GSK takes £2.2bn hit from Avandia claims
January 18, 2011Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone
GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …
GSK moves Crohn’s disease drug into phase III
January 14, 2011Research and Development ChemoCentryx, Crohn’s disease, GSK’786, GlaxoSmithKline, Traficet-EN
GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease. The initial study is a randomised, …
Anti-cancer stem cell drug starts clinical trials
January 14, 2011Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers
OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …
End of the line for GSK’s resveratrol
January 14, 2011Research and Development GSK, GlaxoSmithKline, SRT2104, SRT2379, SRT501, Sirtris, multiple myeloma, resveratrol
GlaxoSmithKline is halting all work on resveratrol, a compound found in red wine and thought to have life extending properties. …
Doctors use GSK’s Pandemrix as seasonal flu vaccines fall short
January 10, 2011Sales and Marketing GSK, GlaxoSmithKline, Pandemrix, flu, h1n1, influenza, vaccines
Doctors may have to use last year’s stock of the H1N1 vaccine Pandemrix as the government admits there are some …
GSK signs £64m autoimmune antibody deal
January 7, 2011Research and Development GSK, GlaxoSmithKline, ImmuTune IMP731, Immutep, autoimmune diseases
GlaxoSmithKline has signed a worldwide licence agreement for a novel antibody designed to treat autoimmune diseases.The company will pay up …
GSK hits back at 60 Minutes whistleblower interview
January 6, 2011Manufacturing and Production 60 Minutes, Avandamet, Bactroban, Cheryl Eckard, GSK, GlaxoSmithKline, Kytril, Paxil, manufacturing compliance
GlaxoSmithKline has responded to an edition of US current affairs show 60 Minutes centring on manufacturing problems at its now-closed …
GSK’s patient access scheme for Votrient sways NICE
December 24, 2010Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …
GSK buys sports nutrition company for £162m
December 14, 2010Sales and Marketing GSK, GlaxoSmithKline, Maximuscle, Maxinutrition, consumer healthcare, sports nutrition
GlaxoSmithKline has acquired UK sports nutrition firm Maxinutrition for £162 million to help broaden its consumer portfolio. The company already …
GSK acquires China’s Nanjing MeiRui Pharma for $70m
December 8, 2010Manufacturing and Production, Sales and Marketing China, GSK, GlaxoSmithKline, Nanjing MeiRui Pharma, Pagoda Pharmaceuticals, SheNiTing
GlaxoSmithKline has continued its expansion into China with the $70 million acquisition of a local firm. Nanjing MeiRui Pharma Co’s …
UK tax reforms prompt £500m manufacturing investment by GSK
November 30, 2010Manufacturing and Production GSK, GlaxoSmithKline, UK corporation tax, patent box, pharma manufacturing
A decision by the UK Government to reform the corporation tax system has been followed by a major job creation …
GlaxoSmithKline forges Russian vaccines alliance
November 30, 2010Manufacturing and Production GSK, GlaxoSmithKline, JSC Binnopharm, cervical cancer vaccine, pharma manufacturing, pneumococcal vaccine, rotavirus vaccine, vaccines
GlaxoSmithKline has announced an alliance with JSC Binnopharm focusing on the secondary manufacture of a number of the pharmaceutical giant’s …
The renal cell carcinoma market: Votrient to challenge Sutent’s lead
November 25, 2010Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma
After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …
GSK partners with Brazil’s Fiocruz on tropical disease research
November 15, 2010Research and Development Chagas disease, Fiocruz, GSK, GSK’s Tres Cantos Medicines Development Campus, GlaxoSmithKline, Oswald Cruz Foundation, leishmaniasis
GlaxoSmithKline and the Brazil-based Oswald Cruz Foundation (Fiocruz) are to research and develop new medicines for tropical diseases Chagas and …
GSK signs rare diseases deal with Amicus
November 1, 2010Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones
GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
